Details of the Drug

General Information of Drug (ID: DM8WAHT)

Drug Name

Fentanyl

Synonyms

fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Analgesia	MB40.8	Approved	[1]
Cancer related pain	MG30	Phase 3	[2]
Pain	MG30-MG3Z	Phase 3	[3]
Chronic pain	MG30	Phase 1	[4]

Therapeutic Class

Neurology Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

336.5

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 1.25 +/- 0.67 mcgh/L [5]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 0.20 +/- 0.06 mcg/L [5]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.69-1.25 h [5]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Bioavailability: The bioavailability of drug is 54% [5]
Clearance: The total plasma clearance of drug is 0.5 L/h/kg [7]
Elimination: 75% of a dose of fentanyl is excreted in the urine with <7% unchanged, and 9% is excreted in the feces with <1% unchanged. [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 7 hours [7]
Metabolism: The drug is metabolized via the cytochrome P450 [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.00032 micromolar/kg/day [9]
Unbound Fraction: The unbound fraction of drug in plasma is 0.16% [10]
Vd: The volume of distribution (Vd) of drug is 25.4 L/kg [11]
Water Solubility: The ability of drug to dissolve in water is measured as 25 mg/mL [6]

Chemical Identifiers

Formula: C22H28N2O
IUPAC Name: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Canonical SMILES: CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
InChI: InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
InChIKey: PJMPHNIQZUBGLI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3345
ChEBI ID: CHEBI:119915
CAS Number: 437-38-7
DrugBank ID: DB00813
TTD ID: D0E1WI
VARIDT ID: DR00430
INTEDE ID: DR0690
ACDINA ID: D00271

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Modulator	[12], [13]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 3A5 (CYP3A5)_{Main DME}	DEIBDNY	CP3A5_HUMAN	Substrate	[16]
Cytochrome P450 3A7 (CYP3A7)_{Main DME}	DERD86B	CP3A7_HUMAN	Substrate	[17]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Analgesia

ICD Disease Classification

MB40.8

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.83E-01	4.69E-02	1.89E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	5.09E-02	-5.62E-02	-5.19E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Fentanyl (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Fentanyl and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[54]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Fentanyl caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[55]
Ivosidenib	DM8S6T7	Major	Increased metabolism of Fentanyl caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[56]
Arn-509	DMT81LZ	Major	Increased metabolism of Fentanyl caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[56]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Fentanyl and Oliceridine.	Acute pain [MG31]	[57]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Fentanyl due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[58]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Fentanyl due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[58]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Fentanyl caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[59]
Methylphenobarbital	DMDSWAG	Major	Increased metabolism of Fentanyl caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[60]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Fentanyl and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[57]
Oxazepam	DMXNZM4	Major	Additive CNS depression effects by the combination of Fentanyl and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[57]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Fentanyl caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[61]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Fentanyl and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[62]
Oritavancin	DM28D05	Moderate	Increased metabolism of Fentanyl caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[55]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Fentanyl caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[61]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Fentanyl caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[61]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Fentanyl caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[61]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Fentanyl caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[61]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Fentanyl caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[63]
Pexidartinib	DMS2J0Z	Major	Increased metabolism of Fentanyl caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[56]
Lapatinib	DM3BH1Y	Major	Decreased metabolism of Fentanyl caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[59]
Tucatinib	DMBESUA	Major	Decreased metabolism of Fentanyl caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[61]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Fentanyl caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[59]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Fentanyl and Dihydrocodeine.	Chronic pain [MG30]	[64]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Fentanyl and Levomilnacipran.	Chronic pain [MG30]	[62]
Atracurium	DM42HXN	Moderate	Additive hypotensive effects by the combination of Fentanyl and Atracurium.	Corneal disease [9A76-9A78]	[65]
Mivacurium	DM473VD	Moderate	Increased risk of bradycardia by the combination of Fentanyl and Mivacurium.	Corneal disease [9A76-9A78]	[65]
Pancuronium	DMB0VY8	Moderate	Increased risk of bradycardia by the combination of Fentanyl and Pancuronium.	Corneal disease [9A76-9A78]	[65]
Propofol	DMB4OLE	Moderate	Additive cardiorespiratory depression effects by the combination of Fentanyl and Propofol.	Corneal disease [9A76-9A78]	[66]
Tubocurarine	DMBZIVP	Moderate	Increased risk of bradycardia by the combination of Fentanyl and Tubocurarine.	Corneal disease [9A76-9A78]	[65]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Fentanyl caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[67]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Fentanyl caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[59]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Fentanyl caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[68]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Fentanyl caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[59]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Fentanyl and Ethanol.	Cystitis [GC00]	[69]
MK-8228	DMOB58Q	Major	Decreased metabolism of Fentanyl caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[61]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Fentanyl and Sertraline.	Depression [6A70-6A7Z]	[62]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Fentanyl and Cyclobenzaprine.	Depression [6A70-6A7Z]	[70]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Fentanyl and Vilazodone.	Depression [6A70-6A7Z]	[62]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Fentanyl caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[61]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Fentanyl and Vortioxetine.	Depression [6A70-6A7Z]	[62]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Fentanyl and Isocarboxazid.	Depression [6A70-6A7Z]	[54]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Fentanyl and Milnacipran.	Depression [6A70-6A7Z]	[62]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Fentanyl and Escitalopram.	Depression [6A70-6A7Z]	[62]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Fentanyl and Desvenlafaxine.	Depression [6A70-6A7Z]	[62]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Fentanyl and OPC-34712.	Depression [6A70-6A7Z]	[57]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Fentanyl and Doxepin.	Depression [6A70-6A7Z]	[62]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Fentanyl and Maprotiline.	Depression [6A70-6A7Z]	[62]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Fentanyl and Esketamine.	Depression [6A70-6A7Z]	[61]
Mepenzolate	DM8YU2F	Moderate	Additive antimotility effects by the combination of Fentanyl and Mepenzolate.	Digestive system disease [DE2Z]	[71]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Fentanyl and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[72]
Oxybutynine	DMJPBAX	Moderate	Additive antimotility effects by the combination of Fentanyl and Oxybutynine.	Discovery agent [N.A.]	[71]
Heroin diacetylmorphine	DMDBWHY	Major	Additive CNS depression effects by the combination of Fentanyl and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[64]
Diazepam	DM08E9O	Major	Additive CNS depression effects by the combination of Fentanyl and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[57]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Fentanyl caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Fentanyl and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[73]
Cenobamate	DMGOVHA	Major	Increased metabolism of Fentanyl caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[56]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Fentanyl caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[61]
Clonazepam	DMTO13J	Major	Additive CNS depression effects by the combination of Fentanyl and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[57]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Fentanyl caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Phenobarbital	DMXZOCG	Major	Additive CNS depression effects by the combination of Fentanyl and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[71]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Fentanyl caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[61]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Fentanyl and Dantrolene.	Fever [MG26]	[57]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Fentanyl caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[55]
Solifenacin	DMG592Q	Moderate	Additive antimotility effects by the combination of Fentanyl and Solifenacin.	Functional bladder disorder [GC50]	[71]
Tolterodine	DMSHPW8	Moderate	Additive antimotility effects by the combination of Fentanyl and Tolterodine.	Functional bladder disorder [GC50]	[71]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Fentanyl caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[61]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Fentanyl caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[74]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Fentanyl caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[61]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Fentanyl caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[55]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Fentanyl caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[61]
Telaprevir	DMMRV29	Major	Decreased metabolism of Fentanyl caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[61]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Fentanyl caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[59]
Rifampin	DMA8J1G	Major	Increased metabolism of Fentanyl caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[68]
Rifapentine	DMCHV4I	Major	Increased metabolism of Fentanyl caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[56]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Fentanyl and Procarbazine.	Hodgkin lymphoma [2B30]	[54]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Fentanyl caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Fentanyl caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Saquinavir	DMG814N	Major	Decreased metabolism of Fentanyl caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Etravirine	DMGV8QU	Major	Increased metabolism of Fentanyl caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Darunavir	DMN3GCH	Major	Decreased metabolism of Fentanyl caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Fentanyl caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Conivaptan	DM1V329	Major	Decreased metabolism of Fentanyl caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[61]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Fentanyl caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[55]
Belladonna	DM2RBWK	Moderate	Additive antimotility effects by the combination of Fentanyl and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[71]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Fentanyl and Suvorexant.	Insomnia [7A00-7A0Z]	[57]
Amobarbital	DM0GQ8N	Major	Increased metabolism of Fentanyl caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[71]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Fentanyl and Ramelteon.	Insomnia [7A00-7A0Z]	[57]
Triazolam	DMETYK5	Major	Additive CNS depression effects by the combination of Fentanyl and Triazolam.	Insomnia [7A00-7A0Z]	[57]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Fentanyl and Zaleplon.	Insomnia [7A00-7A0Z]	[57]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Fentanyl and Tasimelteon.	Insomnia [7A00-7A0Z]	[57]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Fentanyl and Paraldehyde.	Insomnia [7A00-7A0Z]	[57]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Fentanyl and ITI-007.	Insomnia [7A00-7A0Z]	[57]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Fentanyl and Quazepam.	Insomnia [7A00-7A0Z]	[57]
Estazolam	DMZGXUM	Major	Additive CNS depression effects by the combination of Fentanyl and Estazolam.	Insomnia [7A00-7A0Z]	[57]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Fentanyl and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[75]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Fentanyl and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[57]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Fentanyl caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[58]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Fentanyl caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[55]
Ceritinib	DMB920Z	Major	Decreased metabolism of Fentanyl caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[61]
PF-06463922	DMKM7EW	Major	Increased metabolism of Fentanyl caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[56]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Fentanyl caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[58]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Fentanyl caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[59]
Idelalisib	DM602WT	Major	Decreased metabolism of Fentanyl caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[61]
IPI-145	DMWA24P	Major	Decreased metabolism of Fentanyl caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[61]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Fentanyl caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[76]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Fentanyl caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[55]
LGX818	DMNQXV8	Moderate	Increased metabolism of Fentanyl caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[77]
Dabrafenib	DMX6OE3	Major	Increased metabolism of Fentanyl caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[56]
Danazol	DML8KTN	Moderate	Decreased metabolism of Fentanyl caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[59]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Fentanyl and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[78]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Fentanyl and Almogran.	Migraine [8A80]	[62]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Fentanyl and Frovatriptan.	Migraine [8A80]	[62]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Fentanyl and Rizatriptan.	Migraine [8A80]	[62]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Fentanyl and Naratriptan.	Migraine [8A80]	[62]
Exjade	DMHPRWG	Moderate	Increased metabolism of Fentanyl caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[55]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Fentanyl and Thalidomide.	Multiple myeloma [2A83]	[79]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Fentanyl and Ozanimod.	Multiple sclerosis [8A40]	[80]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Fentanyl caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[61]
Nilotinib	DM7HXWT	Major	Decreased metabolism of Fentanyl caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[59]
Dasatinib	DMJV2EK	Major	Decreased metabolism of Fentanyl caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[61]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Fentanyl due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[81]
Metoclopramide	DMFA5MY	Moderate	Additive CNS depression effects by the combination of Fentanyl and Metoclopramide.	Nausea/vomiting [MD90]	[82]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Fentanyl and Granisetron.	Nausea/vomiting [MD90]	[56]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Fentanyl and Ondansetron.	Nausea/vomiting [MD90]	[56]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Fentanyl and Bupropion.	Nicotine use disorder [6C4A]	[83]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Fentanyl caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[59]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Fentanyl and Sibutramine.	Obesity [5B80-5B81]	[84]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Fentanyl and Lorcaserin.	Obesity [5B80-5B81]	[85]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Fentanyl and Dexfenfluramine.	Obesity [5B80-5B81]	[62]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Fentanyl and Levomethadyl Acetate.	Opioid use disorder [6C43]	[64]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Fentanyl and Apraclonidine.	Optic nerve disorder [9C40]	[86]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Fentanyl caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[61]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Fentanyl caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[59]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Fentanyl and Oxymorphone.	Pain [MG30-MG3Z]	[57]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Fentanyl and Levorphanol.	Pain [MG30-MG3Z]	[57]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Fentanyl and Dezocine.	Pain [MG30-MG3Z]	[87]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Fentanyl and Flavoxate.	Pain [MG30-MG3Z]	[71]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Fentanyl and Nalbuphine.	Pain [MG30-MG3Z]	[87]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Fentanyl and Buprenorphine.	Pain [MG30-MG3Z]	[87]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Fentanyl and Safinamide.	Parkinsonism [8A00]	[54]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Fentanyl and Rasagiline.	Parkinsonism [8A00]	[54]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Fentanyl and Pimavanserin.	Parkinsonism [8A00]	[57]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Fentanyl and Orphenadrine.	Parkinsonism [8A00]	[57]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Fentanyl caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[88]
Methylscopolamine	DM5VWOB	Moderate	Additive antimotility effects by the combination of Fentanyl and Methylscopolamine.	Peptic ulcer [DA61]	[71]
Lanreotide acetate	DMG6ZU4	Moderate	Decreased metabolism of Fentanyl caused by Lanreotide acetate mediated inhibition of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[59]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Fentanyl caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[89]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Fentanyl caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[61]
Enzalutamide	DMGL19D	Major	Increased metabolism of Fentanyl caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[56]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Fentanyl due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[58]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Fentanyl due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[58]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Fentanyl and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[90]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Fentanyl due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[58]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Fentanyl due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[58]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Fentanyl due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[58]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Fentanyl due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[58]
Dexamethasone	DMMWZET	Major	Increased metabolism of Fentanyl caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[56]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Fentanyl due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[58]
Quetiapine	DM1N62C	Major	Additive CNS depression effects by the combination of Fentanyl and Quetiapine.	Schizophrenia [6A20]	[91]
Mesoridazine	DM2ZGAN	Major	Additive CNS depression effects by the combination of Fentanyl and Mesoridazine.	Schizophrenia [6A20]	[91]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Fentanyl and Aripiprazole.	Schizophrenia [6A20]	[57]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Fentanyl and Iloperidone.	Schizophrenia [6A20]	[57]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Fentanyl and Paliperidone.	Schizophrenia [6A20]	[57]
Perphenazine	DMA4MRX	Major	Additive CNS depression effects by the combination of Fentanyl and Perphenazine.	Schizophrenia [6A20]	[57]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Fentanyl and Molindone.	Schizophrenia [6A20]	[57]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Fentanyl and Thiothixene.	Schizophrenia [6A20]	[91]
Trifluoperazine	DMKBYWI	Major	Additive CNS depression effects by the combination of Fentanyl and Trifluoperazine.	Schizophrenia [6A20]	[57]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Fentanyl and Asenapine.	Schizophrenia [6A20]	[57]
Pimozide	DMW83TP	Major	Additive CNS depression effects by the combination of Fentanyl and Pimozide.	Schizophrenia [6A20]	[57]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Fentanyl caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[61]
Telotristat ethyl	DMDIYFZ	Major	Increased metabolism of Fentanyl caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[68]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Fentanyl caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[59]
Armodafinil	DMGB035	Major	Increased metabolism of Fentanyl caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[56]
LEE011	DMMX75K	Major	Decreased metabolism of Fentanyl caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[61]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Fentanyl caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[92]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Fentanyl caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[58]
Pipecuronium	DM5F84A	Moderate	Additive hypotensive effects by the combination of Fentanyl and Pipecuronium.	Tonus and reflex abnormality [MB47]	[65]
Doxacurium	DMKE7L9	Moderate	Increased risk of bradycardia by the combination of Fentanyl and Doxacurium.	Tonus and reflex abnormality [MB47]	[65]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Fentanyl and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[90]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Fentanyl and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[90]
Elagolix	DMB2C0E	Major	Increased metabolism of Fentanyl caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[56]
Amiodarone	DMUTEX3	Major	Decreased metabolism of Fentanyl caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[93]
-----------


⏷ Show the Full List of 183 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Carbonic acid disodium salt	E00199	10340	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Potassium bicarbonate	E00425	516893	Alkalizing agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fentanyl 0.1 mg tablet	0.1 mg	Buccal Tablet	Oral
Fentanyl 0.2 mg tablet	0.2 mg	Buccal Tablet	Oral
Fentanyl 0.4 mg tablet	0.4 mg	Buccal Tablet	Oral
Fentanyl 0.6 mg tablet	0.6 mg	Buccal Tablet	Oral
Fentanyl 0.8 mg tablet	0.8 mg	Buccal Tablet	Oral
Fentanyl 0.1 mg tablet	0.1 mg	Sublingual Tablet	Oral
Fentanyl 0.2 mg tablet	0.2 mg	Sublingual Tablet	Oral
Fentanyl 0.3 mg tablet	0.3 mg	Sublingual Tablet	Oral
Fentanyl 0.4 mg tablet	0.4 mg	Sublingual Tablet	Oral
Fentanyl 0.6 mg tablet	0.6 mg	Sublingual Tablet	Oral
Fentanyl 0.8 mg tablet	0.8 mg	Sublingual Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT00822614) Safety of Fentanyl TAIFUN Treatment. U.S. National Institutes of Health.
3	A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin. 2006 Aug;22(8):1493-501.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	FDA Approved Drug Products: Abstral Sublingual Tablet
6	BDDCS applied to over 900 drugs
7	FDA Approved Drug Products: Actiq Transmucosal Lozenge
8	Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11	FDA Approved Drug Products: Fentora Buccal Tablet
12	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
13	Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.Bioorg Med Chem.2006 Oct 1;14(19):6570-80.
14	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15	Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.
16	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A41B and 3A53 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
17	Drug Interactions Flockhart Table
18	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
28	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
29	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
30	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
31	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
32	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
33	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
34	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
35	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
36	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
37	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
38	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
39	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
40	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
41	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
42	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
43	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
44	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
45	Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
46	Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
47	Clinical pipeline report, company report or official report of signaturerx.
48	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
49	Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
50	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
51	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
52	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
53	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
54	Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]
55	Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
56	Canadian Pharmacists Association.
57	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
58	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
59	Labroo RB, Paine MF, Thummel KE, Kharasch ED "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implicaitons for interindividual variability in disposition, efficacy, and drug interactions." Drug Metab Dispos 25 (1997): 1072-80. [PMID: 9311623]
60	Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
61	Cerner Multum, Inc. "Australian Product Information.".
62	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
63	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
64	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
65	Product Information. Alfenta (alfentanil). Janssen Pharmaceutica, Titusville, NJ.
66	Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
67	He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
68	Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
69	Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
70	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
71	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
72	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
73	Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
74	Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
75	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
76	Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
77	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
78	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
79	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
80	Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23. [PMID: 7854515]
81	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
82	Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
83	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
84	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
85	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
86	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
87	Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
88	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
89	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
90	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
91	Cerner Multum, Inc. "Canadian Product Information.".
92	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
93	Gallagher JD, Lieberman RW, Meranze J, Spielman SR, Ellison N "Amiodarone-induced complications during coronary artery surgery." Anesthesiology 55 (1981): 186-8. [PMID: 6973297]